Skip to main content

Drug Efflux Pumps In Cancer Resistance Pathways

In Order to Read Online or Download Drug Efflux Pumps In Cancer Resistance Pathways Full eBooks in PDF, EPUB, Tuebl and Mobi you need to create a Free account. Get any books you like and read everywhere you want. Fast Download Speed ~ Commercial & Ad Free. We cannot guarantee that every book is in the library!

Drug Efflux Pumps in Cancer Resistance Pathways From Molecular Recognition and Characterization to Possible Inhibition Strategies in Chemotherapy

Drug Efflux Pumps in Cancer Resistance Pathways  From Molecular Recognition and Characterization to Possible Inhibition Strategies in Chemotherapy Book
Author : Anonim
Publisher : Academic Press
Release : 2019-11-07
ISBN : 0128141417
Language : En, Es, Fr & De

GET BOOK

Book Description :

Drug Efflux Pumps in Cancer Resistance Pathways: From Molecular Recognition and Characterization to Possible Inhibition Strategies in Chemotherapy, Volume Seven, describes the fundamental aspects of efflux pumps of the ATP-binding cassette superfamily in cancer resistance pathways, along with strategies to target and improve chemotherapy efficacy. Pumps of the ATP-binding cassette superfamily (ABCs) regulate the access of drugs to the intracellular space. In this context, the overexpression of ABCs is a well-known mechanism of multidrug resistance in cancer and is associated with therapeutic failure. Cancer types discussed include breast, endocrine, hematologic, gastrointestinal, musculoskeletal, lung, skin and central nervous system cancers. The book is a valuable source for researchers and advanced students in cancer, biology, pharmacology, pharmaceutical sciences, biomaterials and medical/clinical sciences that are interested in accessing a comprehensive compendium on efflux pumps in mechanisms of cancer resistance. Offers comprehensive and detailed descriptions of the basic aspects of efflux pumps in a very schematic and didactic manner Describes the involvement of efflux pumps in cancer resistance in different cancer types Encompasses an updated overview on state-of-the-art approaches that capitalize on their inhibition to improve chemotherapy and overcome resistance

Drug Resistance in Bacteria Fungi Malaria and Cancer

Drug Resistance in Bacteria  Fungi  Malaria  and Cancer Book
Author : Gunjan Arora,Andaleeb Sajid,Vipin Chandra Kalia
Publisher : Springer
Release : 2017-03-21
ISBN : 3319486837
Language : En, Es, Fr & De

GET BOOK

Book Description :

This book is a compilation of past and recent knowledge in the field of emerging drug resistance. The book covers major aspects of drug resistance in bacteria, fungi, malaria, and cancer.Human survival on earth is constantly threatened by disease and syndrome. From the early days, the aim of research in medicine was to find therapeutic agents that can improve the quality of human life. Although humans are dependent on natural compounds from early days their dependence of drugs increased excessively in last century. The advances in chemistry and biology have helped researchers to identify the drugs that have improved treatment of many diseases. The primary factor for treatment of these diseases is dependent on the efficacy of drugs available. The development of resistance to these drugs is one of the major hindrances. Although there are number of books available on this topic, “drug resistance” biology across kingdoms has never been discussed in a coherent way.

The PI3kinase Pathway and the Susceptibility of Its Inhibitors to ABC Transporters

The PI3kinase Pathway and the Susceptibility of Its Inhibitors to ABC Transporters Book
Author : Ripudaman Singh
Publisher : Unknown
Release : 2012
ISBN : 0987650XXX
Language : En, Es, Fr & De

GET BOOK

Book Description :

The PI3kinase pathway and ABC transporters play a crucial role in normal growth, survival and death of a cell. However in cancer cells, disturbances in these pathways lead to uncontrolled growth even under treatment of various anticancer drugs. Two major efflux pumps i.e. p-glycoprotein (Pgp) and multidrug resistance protein 1 (MRP1) are found to be involved in conferring resistance to vast variety of compounds. Similarly, activated PI3kinse pathway controls many other downstream signal transduction elements that in the end prevent the cancer cells from undergoing apoptosis. This thesis characterises the interaction between PI3kinase pathway and its inhibitors towards major efflux pumps by focussing on susceptibility and structure activity relationship of many compounds. Several clinically available antineoplastic agents and various PI3kinase inhibitors developed in Auckland Cancer Society Research Centre (ACSRC) were used for understanding these two pathways. The first aim was to determine the susceptibility of existing standard compounds in different cell lines. IC50 values of vinblastine and etoposide showed that thymidine incorporation assay had worked effectively. It also showed that the parent CEM, and its derived CEM/E1000 (MRP1 over-expression) and CEM/VLB100 (Pgp over-expression) subline were working properly. After validation of this assay, the next objective was to investigate the susceptibility of pan-PI3kinase isoform inhibitors against resistance. Most of the compounds did not show any significant sign of vulnerability towards both resistant cell lines. Only SN32078 showed susceptibility to resistance in CEM/VLB100 subline. It was observed that conversion of 5-bromo to 5-cyanopyrazolo and methyl to {2-methyl (2-methylamino (ethylamine)} at 5-nitrobenzene had brought this significant change in resistance. The next main aim was to focus on a novel series of compounds synthesized in ACSRC. Most of these compounds were derivatives of PIk-75, a p110 alpha isoform specific inhibitor. These compounds displayed better potency and aqueous stability than PIk-75. Both CEM/E1000 and CEM/VLB100 sublines showed resistance against only few compounds such as SN33070 and SN32932 respectively among this series. Most structural changes were focused on bigger functional groups such as morpholinyl; imidazol-methyl amino; pyridinyl-ethylamino; dimethylaminopropylmethyl amino; methyl sulphonyl piperazinyl amino. SN31842 showed susceptibility towards both Pgp and MRP1 resistant sublines. The other aim was to understand the effect of physicochemical property on resistance profile of cell line. It was observed that no direct or indirect relation could be established between resistance of cell lines and this series of compounds. Structure activity relationship provided us information about various modifications that could increase the potency while reducing the resistance factor. SN31302 was selected based on its low resistance factor in both sublines for investigating its role as a Pgp inhibitor like verapamil. It did reduce IC50 value of vinblastine in CEM/VLB100 subline but on very small scale and hence was not considered as a direct Pgp inhibitor. It must be following some different mechanism to reverse the Pgp overexpression. This shows that these novel compounds have different mode of action on ABC transporter and it could be through protein kinase C and p53 gene.

Using Natural Products to Elucidate a Multidrug Resistance Pathway

Using Natural Products to Elucidate a Multidrug Resistance Pathway Book
Author : Kara Michelle Pearson
Publisher : Unknown
Release : 2000
ISBN : 0987650XXX
Language : En, Es, Fr & De

GET BOOK

Book Description :

Download Using Natural Products to Elucidate a Multidrug Resistance Pathway book written by Kara Michelle Pearson, available in PDF, EPUB, and Kindle, or read full book online anywhere and anytime. Compatible with any devices.

Multiple Drug Resistance in Cancer 2

Multiple Drug Resistance in Cancer 2 Book
Author : Martin Clynes
Publisher : Springer Science & Business Media
Release : 2013-04-17
ISBN : 9401723745
Language : En, Es, Fr & De

GET BOOK

Book Description :

Resistance to chemotherapy, and especially multi-drug resistance, represents a significant barrier to the successful treatment of cancer. This multi-author volume brings together a wide range of up-to-date reviews on different aspects of our knowledge of drug-resistance mechanisms, written by experts in the different areas. Particular attention is paid to recently discovered mechanisms relating to oncogene expression and in particular to proteins involved in regulation and execution of apoptosis. Other important topics covered include DNA repair, topoisomerases, cell cycle control, oxygenation and vascularisation of tumours, LRP, intermediate filament proteins and low-level resistance. Recent developments in understanding the role of efflux pumps (P-170, MRP) in multi-drug resistance are also reviewed. This book will be useful to clinicians and scientists working in the areas of chemotherapy, drug resistance, DNA repair and apoptosis research.

Overcoming Drug Resistance in Gynecologic Cancers

Overcoming Drug Resistance in Gynecologic Cancers Book
Author : Anonim
Publisher : Academic Press
Release : 2021-08-20
ISBN : 0128243007
Language : En, Es, Fr & De

GET BOOK

Book Description :

Overcoming Drug Resistance in Gynecologic Cancers provides up-to-date information related to important gynecologic cancers and focuses on mechanisms of drug resistance, genetics, signaling, immunology, health disparities, nanotechnology, economic considerations and financial impacts. The book covers not only drug resistance but also important means to reverse resistance both in the laboratory and clinic. The book discusses topics such as lifestyle, nutrition and risk of gynecologic cancers, the financial impact of drug resistance, chemosensitizing agents and targeted therapies in cervical, endometrial and ovarian cancer, immunotherapy to overcome drug resistance, and genetic polymorphisms in gynecologic cancers. Additionally, it discusses ethnic and racial health disparity perspectives and future developments in chemosensitizing activities to reverse drug resistance in gynecologic cancers. It is a valuable resource for cancer researchers, oncologists, clinicians and other biomedical field members who are interested in new approaches to improve chemotherapy outcome in patients with gynecologic cancers. Provides a comprehensive resource with all the details needed for readers to understand and follow information Encompasses schematics, diagrams and flow charts in all chapters to help readers easily follow critical information Presents tables and figures especially developed to summarize the information with appropriate statistical rigor and to show details of clinical specimens such as pathological, radiological characteristics, and/or laboratory biomarkers

Drug Resistance in Colorectal Cancer Molecular Mechanisms and Therapeutic Strategies

Drug Resistance in Colorectal Cancer  Molecular Mechanisms and Therapeutic Strategies Book
Author : Chi Hin Cho,Tao Hu
Publisher : Academic Press
Release : 2020-05-24
ISBN : 0128199385
Language : En, Es, Fr & De

GET BOOK

Book Description :

Drug Resistance in Colorectal Cancer: Molecular Mechanisms and Therapeutic Strategies, Volume Eight, summarizes the molecular mechanisms of drug resistance in colorectal cancer, along with the most up-to-date therapeutic strategies available. The book discusses reasons why colorectal tumors become refractory during the progression of the disease, but also explains how drug resistance occurs during chemotherapy. In addition, users will find the current therapeutic strategies used by clinicians in their practice in treating colorectal cancer. The combination of conventional anticancer drugs with chemotherapy-sensitizing agents plays a pivotal role in improving the outcome of colorectal cancer patients, in particular those with drug-resistant cancer cells. From a clinical point-of-view, the content of this book provides clinicians with updated therapeutic strategies for a better choice of drugs for drug-resistant colorectal cancer patients. It will be a valuable source for cancer researchers, oncologists and several members of biomedical field who are dedicated to better treat patients with colorectal cancer. Presents a systemic summary of molecular mechanisms for a quick and in-depth understanding Updates current trends in the field with pioneering information on drug resistance Encompasses both basic and clinical approaches for a better understanding of unsolved problems from a holistic point-of-view

Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance

Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance Book
Author : Andrew Freywald,Franco Vizeacoumar
Publisher : Academic Press
Release : 2020-12-04
ISBN : 0128213116
Language : En, Es, Fr & De

GET BOOK

Book Description :

Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance, Volume 12, discusses new approaches that are being undertaken to counteract tumor plasticity, understand and tackle the interactions with the microenvironment, and disrupt the rewiring of malignant cells or bypass biological mechanism of resistance by using targeted radionuclide therapies. This book provides a unique opportunity to the reader to understand the fundamental causes of drug resistance and how different approaches are applied. It is a one-stop-shop to understand why it is so difficult to treat cancer, and why only a very few patients respond to therapy and a significant portion develop resistance. Despite a rapid development of more effective anti-cancer drugs and combination therapies, cancer remains the leading cause of lethality in the developed world. The main reason for this is the ability of heterogeneous subpopulations of tumor cells interacting with constantly evolving tumor microenvironment to resist elimination and eventually, trigger cancer relapse. In this book, experts review current concepts explaining molecular and biological mechanisms of cancer drug resistance and discussing advancing approaches for overcoming these therapeutic challenges. Provides the most updated knowledge on the mechanisms of cancer drug resistance and the emerging therapeutic approaches reviewed by experts in the field Brings detailed analyses of most important recently reported developments related to drug resistance and their relevance to overcoming it in cancer patients Discusses in-depth molecular mechanisms and novel concepts of cancer resistance to conventional and advanced therapies

Signal and Response Signal Transduction

Signal and Response   Signal Transduction Book
Author : Amrit Rattan K. Baidwan-macfarland
Publisher : Authorhouse UK
Release : 2019-03-30
ISBN : 9781728386867
Language : En, Es, Fr & De

GET BOOK

Book Description :

The ground-breaking scientific study of Amrit Rattan K Baidwan Macfarland (Amrit K Macfarland) asks why and how malignant cancers can be cured. This scientific status is visualised through novel ALL cells lines in vitro, in vivo, and in developing natural human foetal tissues. The resistance status of malignancy to treatment is determined by an inextricable connection between P-gp expression in malignant cell membranes exposed to drugs, blood-brain barrier developmental cells in human foetal cells, and ALL blood cells undergoing chemotherapy. A new type of concept is introduced here as a human P-gp resistance amalgamation (P-gp-MDR) is conceived. Multidrug resistance is created due to cellular and barrier programs through the expression of a membrane drug efflux pump with an ability to create downstream signal transduction systems and which regulates its function and activity. This includes cellular and barrier capacities to generate unforeseen, innovative signalling pathways on multiple levels that can jeopardise treatment pathways at key stages in a fatal way. At present, these systems were unrecognised as potential elements for targeting the killing of deadly malignancies, both in primary and secondary forms. The fact that the blood-brain barrier is such a robust, intelligent entity, interfaced between blood and brain, indicates that it is the essential guardian for the survival of the brain, and thus all human biological systems depend on it. Its expression is seen in developing foetal brain tissues. However, it is also a stumbling block to the eradication of malignant cells. These findings of inducible P-gp expression in cancer cells and those that will constitute the blood-brain barrier creates intense tension both in the malignant systems as well as in the natural systems surrounding them, raising questions as to how to intervene to preserve the normal and retain its autonomy whilst destroying destructive actions, like hijackings by the malignant cells; the source of these abnormal responses remains to be answered. This book dynamically argues that P-gp MDR 1 and MDR 3 and the expressive Pg-p brain-blood functions are necessary to address for new chemotherapeutic challenges. It is important to study in general and specific, intelligent malignant, and natural systems that create multidrug resistance to treatment. The creativity and actions of P-gp and its polymorphisms are distinct in natural cells and malignant cells, and P-gp and its polymorphisms are involved in the creation of acute multidrug resistance, and they act as deadly programmed protectors of the biological environments of malignant cells and the cells exposed to drug treatments. As such the structure and function of P-gp together constitutes fatal ends for the host and its systems - based on studies of human cell lines, in vitro systems, in vivo foetal systems, in vivo blood cell systems - and exhibits non-cooperation of cells to multidrug treatments. In short, ALL is a multifaceted disease and displays abnormal activation of signalling pathways, which in turn activate drug-resistance pumps. The ability to target elements that activate the drug transporter P-gp will then be key to success to overcome cancers in this cutting edge field of nano-micro-molecular genetics. AUTHORHOUSE - ACADEMIC PRESS

Therapeutic Strategies to Overcome ALK Resistance in Cancer

Therapeutic Strategies to Overcome ALK Resistance in Cancer Book
Author : Luc Friboulet
Publisher : Academic Press
Release : 2021-01-18
ISBN : 0128217790
Language : En, Es, Fr & De

GET BOOK

Book Description :

Therapeutic Strategies to Overcome ALK Resistance in Cancer, Volume 13, presents current strategies to improve and prolong clinical benefit in ALK driven cancers. Most patients with ALK-driven cancer are sensitive to tyrosine kinase inhibitor (TKI) therapy, but resistance invariably develops. This book discusses topics such as structure and function of ALK, ALK rearranged lung cancer, resistance mechanisms to ALK TKI tumors, and novel therapeutic strategies to enhance crizotinib anti-tumor efficacy in ALCL. Additionally, it encompasses information on drug combinations to enhance ALK TKI anti-tumor efficacy in neuroblastoma and future perspectives in the field. This book is a valuable resource for cancer researchers, clinicians and several members of biomedical field who need to understand more about how to fight ALK resistance in cancer treatment. Explains the biology of ALK RTK, focusing on its tissue expression, structure and functionality Presents an overview of current treatments and the benefits of ALK TKI in lung and other cancer types, such as ALCL, neuroblastoma and inflammatory myofibroblastic tumor Encompasses information on systemic treatments other than TKI, including chemotherapy, immunotherapy and antiangiogenic agents in ALK-driven NSCLC

Overcoming Ovarian Cancer Chemoresistance

Overcoming Ovarian Cancer Chemoresistance Book
Author : Goli Samimi,Christina Annunziata
Publisher : Academic Press
Release : 2020-11-06
ISBN : 0128198419
Language : En, Es, Fr & De

GET BOOK

Book Description :

Overcoming Ovarian Cancer Chemoresistance presents non-overlapping review chapters that discuss the state of the field in overcoming chemoresistance of ovarian cancer and treatment options before and following recurrence, considering the genetic makeup of the ovarian cancer patient and her tumor. With the uptake of both germline and somatic gene testing, clinicians can obtain a more comprehensive understanding of ovarian tumors and this book provides information to link the genetic makeup of a tumor (or patient) with the best available treatment. The book discusses topics such as strategies to fight chemo-resistance in ovarian cancer, circulating DNA as a monitor of response, BRCA mutations, ovarian cancer stem cells, immunotherapy and vaccines. Additionally, it brings a list of promising agents at clinical and pre-clinical stage that will impact the treatment in the near future. This book is a valuable source for cancer researchers, oncologists and several members of biomedical field who need to understand how to battle chemoresistance in ovarian cancer. Provides a comprehensive view of both biological and genetic determinants of resistance, as well as technical approaches to monitor response Discusses genetic reversions as a unique alteration and a new field of study Includes a chapter on upcoming and promising agents that are in the pre-clinical and early clinical space, to set the stage for future directions in the field

Glioblastoma Resistance to Chemotherapy Molecular Mechanisms and Innovative Reversal Strategies

Glioblastoma Resistance to Chemotherapy  Molecular Mechanisms and Innovative Reversal Strategies Book
Author : Ramasamy Paulmurugan,Tarik F. Massoud
Publisher : Academic Press
Release : 2021-06-25
ISBN : 0128215682
Language : En, Es, Fr & De

GET BOOK

Book Description :

Glioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies brings current knowledge from an international team of experts on the science and clinical management of glioblastoma chemoresistance. The book discusses topics such as molecular mechanisms of chemoresistance, experimental models to study chemoresistance, chemoresistance to drugs other than Temozolomide, and specific strategies to reverse chemoresistance. Additionally, it encompasses information on how to mitigate chemoresistance by targeted enhancement of p53 function. This book is a valuable resource for cancer researchers, oncologists, neuro-oncologists and other members of the biomedical field. Glioblastoma (GBM) is the most invasive and malignant primary brain tumor in humans with poor survival after diagnosis, therefore it is imperative that molecular and cellular mechanisms behind therapy resistant GBM cells, as well as the therapeutic strategies available to counter the resistance are comprehensively understood. Provides comprehensive, core knowledge related to the entire discipline of glioblastoma chemoresistance, from its many etiological mechanisms, to specific strategies to reverse resistance Presents current information from an international team of experts on the basic science, pre-clinical research, and clinical management of glioblastoma chemoresistance Discusses molecular and cellular mechanisms behind therapy resistant glioblastoma cells, as well as the therapeutic strategies available to counter this resistance

New Targeting in The Reversal of Resistant Glioblastomas

New Targeting in The Reversal of Resistant Glioblastomas Book
Author : Ali Syed Arbab
Publisher : Academic Press
Release : 2021-03-18
ISBN : 0128232765
Language : En, Es, Fr & De

GET BOOK

Book Description :

New Targeting in The Reversal of Resistant Glioblastomas discusses alternative treatment strategies that not only target tumor cells but also target the tumor microenvironment, metabolic pathways and interaction of cytokines in tumor cells. The current treatment for primary and recurrent glioblastomas is failing because clinicians are not considering the effect of bone marrow derived cells to the development of resistance to clinically practiced therapies. This book helps readers rethink treatment strategies to successfully fight glioblastomas. It is a valuable resource for cancer researchers, clinicians, graduate students and other members of the biomedical field. Explains the effect of bone marrow derived cells on the development of resistance to clinically practiced therapies Provides information on the availability of alternate therapies for recurrent glioblastoma when standard practices have failed Discusses targeting tumor microenvironment using available FDA approved drugs as an alternative treatment strategy for glioblastoma

Epigenetic Regulation in Overcoming Chemoresistance

Epigenetic Regulation in Overcoming Chemoresistance Book
Author : Chunfu Wu,Lihui Wang
Publisher : Academic Press
Release : 2021-06-26
ISBN : 012823685X
Language : En, Es, Fr & De

GET BOOK

Book Description :

Epigenetic Regulation in Overcoming Chemoresistance, Volume 19, explains how epigenetic agents can enhance the chemotherapy sensitivity of diverse types of cancers. The book provides a comprehensive delineation and the recent development of the scientific studies on the epigenetic regulation in enhancing chemo-sensitivity. In addition, it discusses several topics such as DNA methyltransferase inhibitors (DNMTi), Histone deacetylases inhibitors (HDACi), Histone lysine demethylases inhibitors (HDMi), Histone lysine methyltransferases inhibitors (HMTi) and drugs regulating the microRNA, long non-coding RNA (lncRNA) or RNA methylation. Finally, recent and future developments of the field of epigenetic regulation are explored. This is a valuable resource for cancer researchers, clinicians, graduate students and several members of biomedical field who are interested in learning about epigenetic regulation methods to reverse chemo-resistance in cancers. Presents detailed diagrams of the mechanisms of epigenetic regulation for easy consult Encompasses multiple clinical trial summary diagrams to help readers quickly and clearly get information from clinical trials Provides future perspectives in each section to inspire readers to use epigenetic regulation to overcome chemo-resistance

pH Interfering Agents as Chemosensitizers in Cancer Therapy

pH Interfering Agents as Chemosensitizers in Cancer Therapy Book
Author : Claudiu Supuran,Simone Carradori
Publisher : Academic Press
Release : 2020-09-15
ISBN : 0128209283
Language : En, Es, Fr & De

GET BOOK

Book Description :

pH Interfering Agents as Chemosensitizers In Cancer Therapy, Volume Thirteen, provides a detailed overview of the chemosensitizers for the treatment of cancer spanning from biochemical and structural features to pharmacology and drug-design, including technological applications. The book is structured with innovative outlines and a distinction between experimental and clinical results. The continuous discovery and assessment of the role played by old/new synthetic drugs, natural compounds and technological applications has led to the urgent need of classification in terms of biological activity, mechanism of action, clinical outcomes, cancer cell lines sensible to the treatment, and potentialities to better orient research in this field. Moreover, all the aspects relevant for medicinal chemistry (drug design, structure-activity relationships, permeability data, cytotoxicity, appropriate statistical procedures, and molecular modeling studies) are strictly considered. Presents a broad view of the topic according to a medicinal chemistry-based approach beyond syntheses and biological assays, focusing on SAR studies, chemoinformatic, drug targeting and molecular modeling Explains the mechanism of action of the chemosensitizers by means of schemes and figures to facilitate comprehension Discusses novel targets to explore new possibilities that enhance research in the field

Novel Therapies in Head and Neck Cancer Beyond the Horizon

Novel Therapies in Head and Neck Cancer  Beyond the Horizon Book
Author : Maie A. St. John,No hee Park
Publisher : Academic Press
Release : 2020-06-29
ISBN : 0128209291
Language : En, Es, Fr & De

GET BOOK

Book Description :

Novel Therapies in Head and Neck Cancer: Beyond the Horizon, Volume Twelve, provides a high-level synthesis of the latest treatments and outcomes relating to head and neck cancer. Chemotherapy and immunotherapy for those cancer types are rapidly evolving, and an updated source based on the expertise of internationally renowned researchers is necessary. This book discusses the outcome of recent trials using chemotherapy, novel approaches for HPV+ SCCA, cases in which immunotherapy is more likely to be successful, and precision medicine based on target therapies. Additionally, new approaches for rare diseases in head and neck and novel drug delivery platforms are presented. This book will be a very useful source so that students, scientists and clinicians who can be facile with the data, build on what is known, and continue to offer cutting-edge, validated therapies to all patients. Covers new chemotherapy trials, specifically on HPV and non-HPV related cancer types Discusses the application of immunotherapy to treat rare types of head and neck cancer Presents updated information on targeted therapies, specifically focusing on skin cancer in the region

Repurposed Drugs Targeting Cancer Signaling Pathways Clinical Insights to Improve Oncologic Therapies

Repurposed Drugs Targeting Cancer Signaling Pathways  Clinical Insights to Improve Oncologic Therapies Book
Author : Alma D. Campos-Parra,Carlos Pérez-Plasencia,Teresita Padilla-Benavides,Eduardo López-Urrutia
Publisher : Frontiers Media SA
Release : 2021-08-26
ISBN : 2889712397
Language : En, Es, Fr & De

GET BOOK

Book Description :

Download Repurposed Drugs Targeting Cancer Signaling Pathways Clinical Insights to Improve Oncologic Therapies book written by Alma D. Campos-Parra,Carlos Pérez-Plasencia,Teresita Padilla-Benavides,Eduardo López-Urrutia, available in PDF, EPUB, and Kindle, or read full book online anywhere and anytime. Compatible with any devices.

Colon Cancer Diagnosis and Therapy

Colon Cancer Diagnosis and Therapy Book
Author : Naveen Kumar Vishvakarma
Publisher : Springer Nature
Release : 2021-10-27
ISBN : 3030646688
Language : En, Es, Fr & De

GET BOOK

Book Description :

Colorectal cancer (CRC) is a major global health challenge as the third leading cause for cancer related mortalities worldwide. Despite advances in therapeutic strategies, the five-year survival rate for CRC patients has remained the same over time due to the fact that patients are often diagnosed in advanced metastatic stages. Drug resistance is another common reason for poor prognosis. Researchers are now developing advanced therapeutic strategies such as immunotherapy, targeted therapy, and combination nanotechnology for drug delivery. In addition, the identification of new biomarkers will potentiate early stage diagnosis. This book is the second of three volumes on recent developments in colorectal diagnosis and therapy. Each volume can be read on its own, or together. Each volume focuses on different novel therapeutic advances, biomarkers, and identifies therapeutic targets for treatment. Written by leading international experts in the field, coverage addresses the role of diet habits and lifestyle in reducing gastrointestinal disorders and incidence of CRC. Chapters discuss current and future diagnostic and therapeutic options for colorectal cancer patients, focusing on immunotherapeutics, nanomedicine, biomarkers, and dietary factors for the effective management of colon cancer.

Epidemiology of Endocrine Tumors

Epidemiology of Endocrine Tumors Book
Author : Jahangir Moini,Craig Badolato,Raheleh Ahangari
Publisher : Elsevier
Release : 2021-02-17
ISBN : 0128232668
Language : En, Es, Fr & De

GET BOOK

Book Description :

Epidemiology of Endocrine Tumors brings current data and clinical research into one source for a multidisciplinary audience. The book discusses the prevalence, incidence, etiology, pathology, diagnosis and treatment of various endocrine tumors. With clear and focused writing, it is essential reading for healthcare professionals, endocrinologists, oncologists, and public health professionals. Users will be able to bridge the knowledge gap that exists in the comprehensive coverage surrounding the epidemiology of endocrine tumors. Globally, the prevalence and incidence of endocrine tumors is high. This audience needs a treatise where they can gain a broad overview of endocrine tumors with a focus on epidemiology. Supplies information about the epidemiology of various endocrine tumors, both benign and malignant, to endocrinologists, oncologists and related health care professionals Focuses on the impact upon costs and patient deaths due to complications of these tumors Describes how endocrine tumors affect various age groups and ethnicities, discussing the prevention of endocrine tumors Presents chapters on Cancer Problem, Specific Endocrine Tumors, Prevention, Detection and Diagnosis, and Treatment of Endocrine Tumors Provides review questions with an answer key and detailed glossary

Multidrug Resistance in Cancer Pharmacological Strategies from Basic Research to Clinical Issues

 Multidrug Resistance in Cancer  Pharmacological Strategies from Basic Research to Clinical Issues Book
Author : Stefania Nobili,Enrico Mini,Chiara Riganti
Publisher : Unknown
Release : 2015-07-06
ISBN : 2889196151
Language : En, Es, Fr & De

GET BOOK

Book Description :

More than 40 years ago, the observation that doxorubicin-resistant tumor cells were cross-resistant to several structurally different anticancer agents was the first step in the discovery of P-glycoprotein (P-gp). P-gp belongs to the superfamily of ATP-binding cassette (ABC) transporters;its overexpression has become a therapeutic target for overcoming multidrug resistance in tumors. However, P-gp is also expressed in cells of normal tissues where it plays a physiological role, by protecting them from the toxic effects of xenobiotics. Also, ABCB1 gene polymorphisms may influence the response to anticancer drugs substrate of P-gp. Several strategies to overcome P-gp tumor drug resistance have been suggested. P-gp 'circumvention’ is the most explored and is based on the coadministration of anticancer agents and pump inhibitors (P-gp modulators). Despite the positive findings obtained in preclinical studies, results of clinical trials are not yet successful and clinical research is still ongoing. Other investigational approaches have been studied (e.g. P-gp targeting antibodies, use of antisense strategies or transcriptional regulators targeting ABCB1 gene expression) but their use is still circumscribed to the preclinical setting. A further approach is represented by the encapsulation of P-gp substrate anticancer drugs into liposomes or nanoparticles. This strategy has shown higher efficacy in tumor previously treated with the free drug. The reasons explaining the increased efficacy of liposomal/nanoparticle-based drugs in Pgp-overexpressing tumors include the coating with specific surfactants, the composition changes in the plasma membrane microdomains where P-gp is embedded, the direct impairment of P-gp catalytic mechanisms exerted by specific component of the liposomal shell, but are not yet fully understood. A second strategy to overcome P-gp tumor drug resistance is represented by exploiting the P-gp presence. Actually, P-gp-overexpressing cells show increased sensitivity (collateral sensitivity) to some drugs (e.g. verapamil, narcotic analgesics) and to some investigational compounds (e.g. NSC73306). P-gp-overexpressing cell are hypersensitive to reactive oxygen species, to agents perturbing the energetic metabolic pathways, changing the membrane compositions, reducing the efflux of endogenous toxic catabolites. However, the mechanisms explaining collateral sensitivity have not been fully elucidated. Another approach to exploit P-gp is represented by ABCB1 gene transfer to transform bone marrow progenitor cells into a drug resistant state which may allow conventional or higher doses of anticancer drug substrates of P-gp to be administered safely after transplantation. More recently the development and introduction in the clinics of anticancer drugs which are not substrates of P-gp (e.g. new microtubule modulators, topoisomerase inhibitors) has provided a new and promising strategy to overcome P-gp tumor drug resistance (P-gp 'evasion'). This ‘research topic’ issue aims at exploding the above mentioned matters, in particular by: -retracing the history of the first researches on P-gp - describing the physiological role of P-gp - describing the molecular basis, structural features and mechanism of action of P-gp - describing diagnostic laboratory methods useful to determine the expression of P-gp and its transporter function - describing strategies to overcome tumor drug resistance due to P-gp and other ABC transporters - indicating novel approaches to overcome P-gp multidrug resistance, ranging from basic research studies to pre-clinical/clinical studies.